ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	14.94B
Revenue (ttm)	3.19B
Net Income (ttm)	204.67M
Shares Out	790.74M
EPS (ttm)	0.26
PE Ratio	73.02
Forward PE	52.50
Dividend	0.35 (1.85%)
Ex-Dividend Date	Jul 3, 2025

Volume	484,309
Average Volume	949,827
Open	19.10
Previous Close	18.90
Day's Range	18.75 - 19.10
52-Week Range	16.25 - 25.80
Beta	0.32
RSI	56.72
Earnings Date	Nov 5, 2025

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, India, the United States and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CRAM services, such as chemistry skill, analytical...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2024, ScinoPharm Taiwan's revenue was 3.41 billion, an increase of 6.91% compared to the previous year's 3.19 billion. Earnings were 339.35 million, an increase of 18.22%.